vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and PRA GROUP INC (PRAA). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $333.4M, roughly 1.8× PRA GROUP INC). EXELIXIS, INC. runs the higher net margin — 40.8% vs 17.0%, a 23.9% gap on every dollar of revenue. On growth, PRA GROUP INC posted the faster year-over-year revenue change (13.7% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $-90.4M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 14.2%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
PRA Group, Inc. is a publicly traded debt buyer and debt collection company based in Norfolk, Virginia. The company buys delinquent consumer debt from credit card issuers and other financial institutions at a discount and pursues collection of the full debt owed. Founded in 1996, PRA Group employs more than 3200 people in 18 countries.
EXEL vs PRAA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $333.4M |
| Net Profit | $244.5M | $56.5M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | 37.7% |
| Net Margin | 40.8% | 17.0% |
| Revenue YoY | 5.6% | 13.7% |
| Net Profit YoY | 74.8% | 206.3% |
| EPS (diluted) | $0.89 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $333.4M | ||
| Q3 25 | $568.3M | $311.1M | ||
| Q2 25 | $555.4M | $287.7M | ||
| Q1 25 | $566.8M | $269.6M | ||
| Q4 24 | — | $293.2M | ||
| Q3 24 | $539.5M | $281.5M | ||
| Q2 24 | $637.2M | $284.2M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $56.5M | ||
| Q3 25 | $184.8M | $-407.7M | ||
| Q2 25 | $159.6M | $42.4M | ||
| Q1 25 | $139.9M | $3.7M | ||
| Q4 24 | — | $18.5M | ||
| Q3 24 | $118.0M | $27.2M | ||
| Q2 24 | $226.1M | $21.5M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 37.7% | ||
| Q3 25 | 37.6% | -101.4% | ||
| Q2 25 | 33.6% | 29.6% | ||
| Q1 25 | 28.8% | 27.7% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | 25.2% | 32.0% | ||
| Q2 24 | 43.3% | 31.4% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 17.0% | ||
| Q3 25 | 32.5% | -131.0% | ||
| Q2 25 | 28.7% | 14.7% | ||
| Q1 25 | 24.7% | 1.4% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | 21.9% | 9.6% | ||
| Q2 24 | 35.5% | 7.6% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $1.47 | ||
| Q3 25 | $0.65 | $-10.43 | ||
| Q2 25 | $0.55 | $1.08 | ||
| Q1 25 | $0.47 | $0.09 | ||
| Q4 24 | — | $0.47 | ||
| Q3 24 | $0.40 | $0.69 | ||
| Q2 24 | $0.77 | $0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $104.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $979.9M |
| Total Assets | $2.8B | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $104.4M | ||
| Q3 25 | $791.1M | $107.5M | ||
| Q2 25 | $1.0B | $131.6M | ||
| Q1 25 | $1.1B | $128.7M | ||
| Q4 24 | — | $105.9M | ||
| Q3 24 | $1.2B | $141.1M | ||
| Q2 24 | $1.0B | $118.9M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $979.9M | ||
| Q3 25 | $2.0B | $928.5M | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $2.2B | $1.2B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $2.3B | $1.2B | ||
| Q2 24 | $2.1B | $1.1B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $5.1B | ||
| Q3 25 | $2.7B | $5.0B | ||
| Q2 25 | $2.8B | $5.4B | ||
| Q1 25 | $2.9B | $5.1B | ||
| Q4 24 | — | $4.9B | ||
| Q3 24 | $3.0B | $4.9B | ||
| Q2 24 | $2.8B | $4.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $-85.5M |
| Free Cash FlowOCF − Capex | $332.4M | $-90.4M |
| FCF MarginFCF / Revenue | 55.5% | -27.1% |
| Capex IntensityCapex / Revenue | 0.2% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.36× | -1.51× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $-169.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $-85.5M | ||
| Q3 25 | $49.0M | $-10.1M | ||
| Q2 25 | $211.4M | $-12.9M | ||
| Q1 25 | $240.3M | $-52.6M | ||
| Q4 24 | — | $-94.6M | ||
| Q3 24 | $271.3M | $-35.0M | ||
| Q2 24 | $119.5M | $-29.5M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $-90.4M | ||
| Q3 25 | $46.2M | $-11.3M | ||
| Q2 25 | $208.5M | $-14.2M | ||
| Q1 25 | $236.3M | $-53.5M | ||
| Q4 24 | — | $-98.6M | ||
| Q3 24 | $263.1M | $-36.1M | ||
| Q2 24 | $113.0M | $-30.8M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | -27.1% | ||
| Q3 25 | 8.1% | -3.6% | ||
| Q2 25 | 37.5% | -4.9% | ||
| Q1 25 | 41.7% | -19.8% | ||
| Q4 24 | — | -33.6% | ||
| Q3 24 | 48.8% | -12.8% | ||
| Q2 24 | 17.7% | -10.8% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 1.4% | ||
| Q3 25 | 0.5% | 0.4% | ||
| Q2 25 | 0.5% | 0.4% | ||
| Q1 25 | 0.7% | 0.3% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | 1.5% | 0.4% | ||
| Q2 24 | 1.0% | 0.5% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | -1.51× | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 1.32× | -0.30× | ||
| Q1 25 | 1.72× | -14.37× | ||
| Q4 24 | — | -5.13× | ||
| Q3 24 | 2.30× | -1.29× | ||
| Q2 24 | 0.53× | -1.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
PRAA
| GB | $170.1M | 51% |
| Other | $163.3M | 49% |
